Search results for "From ACP Internist"
Apixaban shows superior effectiveness, safety compared to rivaroxaban
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
https://gastroenterology.acponline.org/archives/2021/12/17/6.htm
17 Dec 2021
Apixaban associated with lower risk of GI bleeding compared to other DOACs
Apixaban users experienced similar rates of ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality as patients taking other direct oral anticoagulants (DOACs), a retrospective analysis found.
https://gastroenterology.acponline.org/archives/2022/11/18/6.htm
18 Nov 2022
Best practices for HCV care include less invasive testing for many patients, says ACP
The College's new advice on treating hepatitis C virus (HCV) identifies patients who can be safely treated in primary care with laboratory monitoring limited to the beginning and end of treatment and no invasive testing.
https://gastroenterology.acponline.org/archives/2020/10/23/6.htm
23 Oct 2020
Recurrent C. difficile infections more than doubled between 2001 and 2012
Risk factors for recurrence include age; sex; and use of antibiotics, proton-pump inhibitors, or corticosteroids. These factors could adjust treatment algorithms for high-risk patients, including earlier use of fecal transplant.
https://gastroenterology.acponline.org/archives/2017/07/28/7.htm
28 Jul 2017
USPSTF expands hepatitis C screening recommendation to most adults
All adults ages 18 to 79 years should now be screened at least once, but people who use injection drugs and pregnant women may require screening more often.
https://gastroenterology.acponline.org/archives/2020/03/27/6.htm
27 Mar 2020
Task Force lowers age for colorectal cancer screening to begin
The U.S. Preventive Services Task Force recommended colorectal cancer screening begin at age 45 years based on an evidence review finding with moderate certainty that the net benefit is moderate to substantial.
https://gastroenterology.acponline.org/archives/2021/05/28/7.htm
28 May 2021
Lipophilic statins associated with significantly reduced hepatocellular carcinoma incidence, mortality in hepatitis
Potential benefits of lipophilic statins appeared to be dose- and duration-dependent, with the greatest reduction in hepatocellular carcinoma risk seen with use of a moderate-dose statin for about two years, according to data from a registry of Swedish patients with hepatitis B or C.
https://gastroenterology.acponline.org/archives/2019/08/23/7.htm
23 Aug 2019
Model supports high-intensity surveillance after detection of colorectal adenomas
The target population was U.S. patients ages 50, 60, or 70 years with low-risk or high-risk adenomas removed after screening via colonoscopy or fecal immunochemical testing.
https://gastroenterology.acponline.org/archives/2019/09/27/10.htm
27 Sep 2019
Financial incentives associated with increased FIT uptake but not increased CRC screening overall
A three-arm trial of incentives for fecal immunochemical testing (FIT) and colorectal cancer screening (CRC) tested mail-only, mail and monetary, and mail and lottery interventions.
https://gastroenterology.acponline.org/archives/2019/07/26/7.htm
26 Jul 2019
AGA releases guidelines on managing gastric intestinal metaplasia found during routine endoscopy
The guidelines from the American Gastroenterological Association (AGA) will aid clinicians' decision making for patients undergoing upper endoscopy in North America, the authors said.
https://gastroenterology.acponline.org/archives/2019/12/27/7.htm
27 Dec 2019